{
  "symbol": "UNH",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1718,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.167
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 41,913 $ 23,365 Short-term investments 4,584 4,546 Accounts receivable, net 22,414 17,681 Other current receivables, net 14,696 12,769 Assets under management 3,837 4,087 Prepaid expenses and other current assets 6,451 6,621 Total current assets 93,895 69,069 Long-term investments 46,884 43,728 Property, equipment and capitalized software, net 10,637 10,128 Goodwill 100,406 93,352 Other intangible assets, net 16,165 14,401 Other assets 15,692 15,027 Total assets $ 283,679 $ 245,705 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 31,809 $ 29,056 Accounts payable and accrued liabilities 29,856 27,715 Short-term borrowings and current maturities of long-term debt 9,931 3,110 Unearned revenues 14,487 3,075 Other current liabilities 30,399 26,281 Total current liabilities 116,482 89,237 Long-term debt, less current maturities 60,657 54,513 Deferred income taxes 2,834 2,769 Other liabilities 13,084 12,839 Total liabilities 193,057 159,358 Commitments and contingencies (Note 6) Redeemable noncontrolling interests 4,801 4,897 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 932 and 934 issued and outstanding 9 9 Retained earnings 88,852 86,156 Accumulated other comprehensive loss ( 7,549 ) ( 8,393 ) Nonredeemable noncontrolling interests 4,509 3,678 Total equity 85,821 81,450 Total liabilities, redeemable noncontrolling interests and equity $ 283,679 $ 245,705 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, (in millions, except per share data) 2023 2022 Revenues: Premiums $ 72,786 $ 64,070 Products 10,267 9,340 Services 8,080 6,372 Investment and other income 798 367 Total revenues 91,931 80,149 Operating costs: Medical costs 59,845 52,523 Operating costs 13,625 11,401 Cost of products sold 9,405 8,487 Depreciation and amortization 970 788 Total operating costs 83,845 73,199 Earnings from operations 8,086 6,950 Interest expense ( 754 ) ( 433 ) Earnings before income taxes 7,332 6,517 Provision for income taxes ( 1,558 ) ( 1,369 ) Net earnings 5,774 5,148 Earnings attributable to noncontrolling interests ( 163 ) ( 121 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,611 $ 5,027 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 6.01 $ 5.34 Diluted $ 5.95 $ 5.27 Basic weighted-average number of common shares outstanding 933 941 Dilutive effect of common share equivalents 10 13 Diluted weighted-average number of common shares outstanding 943 954 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 5 2 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended March 31, (in millions) 2023 2022 Net earnings $ 5,774 $ 5,148 Other comprehensive income (loss): Gross unrealized gains (losses) on investment securities during the period 640 ( 2,023 ) Income tax effect ( 147 ) 465 Total unrealized gains (losses), net of tax 493 ( 1,558 ) Gross reclassification adjustment for net realized losses (gains) included in net earnings 13 ( 3 ) Income tax effect ( 3 ) 1 Total reclassification adjustment, net of tax 10 ( 2 ) Total foreign currency translation gains 341 918 Other comprehensive income (loss) 844 ( 642 ) Comprehensive income 6,618 4,506 Comprehensive income attributable to noncontrolling interests ( 163 ) ( 121 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 6,455 $ 4,385 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2023 934 $ 9 $ \u2014 $ 86,156 $ ( 2,778 ) $ ( 5,615 ) $ 3,678 $ 81,450 Net earnings 5,611 113 5,724 Other comprehensive income 503 341 844 Issuances of common stock, and related tax effects 2 \u2014 350 350 Share-based compensation 366 366 Common share repurchases ( 4 ) \u2014 ( 633 ) ( 1,378 ) ( 2,011 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,537 ) ( 1,537 ) Redeemable noncontrolling interests fair value and other adjustments ( 83 ) ( 83 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 819 819 Distribution to nonredeemable noncontrolling interests ( 101 ) ( 101 ) Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 Balance at January 1, 2022 941 $ 10 $ \u2014 $ 77,134 $ 423 $ ( 5,807 ) $ 3,285 $ 75,045 Net earnings 5,027 88 5,115 Other comprehensive (loss) income ( 1,560 ) 918 ( 642 ) Issuances of common stock, and related tax effects 3 \u2014 333 333 Share-based compensation 282 282 Common share repurchases ( 5 ) \u2014 ( 484 ) ( 2,016 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.45 per share) ( 1,363 ) ( 1,363 ) Redeemable noncontrolling interests fair value and other adjustments ( 131 ) ( 131 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 91 91 Distribution to nonredeemable noncontrolling interests ( 102 ) ( 102 ) Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2023 2022 Operating activities Net earnings $ 5,774 $ 5,148 Noncash items: Depreciation and amortization 970 788 Deferred income taxes ( 332 ) 161 Share-based compensation 362 299 Other, net 69 17 Net change in other operating items, net of effects from acquisitions and changes in AARP balances: Accounts receivable ( 4,306 ) ( 4,521 ) Other assets ( 1,875 ) ( 1,089 ) Medical costs payable 2,467 3,849 Accounts payable and other liabilities 1,796 589 Unearned revenues 11,402 78 Cash flows from operating activities 16,327 5,319 Investing activities Purchases of investments ( 4,894 ) ( 4,982 ) Sales of investments 456 1,591 Maturities of investments 2,119 1,759 Cash paid for acquisitions, net of cash assumed ( 7,826 ) ( 1,231 ) Purchases of property, equipment and capitalized software ( 760 ) ( 555 ) Other, net ( 115 ) ( 255 ) Cash flows used for investing activities ( 11,020 ) ( 3,673 ) Financing activities Common share repurchases ( 2,000 ) ( 2,500 ) Cash dividends paid ( 1,537 ) ( 1,363 ) Proceeds from common stock issuances 344 551 Repayments of long-term debt ( 1,375 ) ( 1,100 ) Proceeds from short-term borrowings, net 7,349 3,148 Proceeds from issuance of long-term debt 6,401 \u2014 Customer funds administered 5,012 5,120 Other, net ( 1,004 ) ( 1,552 ) Cash flows from financing activities 13,190 2,304 Effect of exchange rate changes on cash and cash equivalents 51 157 Increase in cash and cash equivalents 18,548 4,107 Cash and cash equivalents, beginning of period 23,365 21,375 Cash and cash equivalents, end of period $ 41,913 $ 25,482 See Notes to the Condens\n ) $ 6,517 13 Table of Contents ITEM\u00a02.",
      "score": 0.998
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,027 $ 487 $ (3,684) $ (8,701) 1 513 244 (1,894) (4,741) (1) (513) (216) 1,979 5,729 (2) (1,027) (428) 4,008 12,724 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,027 $ 487 $ (3,684) $ (8,701) 1 513 244 (1,894) (4,741) (1) (513) (216) 1,979 5,729 (2) (1,027) (428) 4,008 12,724 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "income tax rate applicable to corporations); increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete, manage or integrate strategic transactions; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; fluctuations in foreign currency exchange rates; failure to attract, \nh\u00a031, 2023, our debt to debt-plus-shareholders\u2019 equity ratio, as defined and calculated under the credit facilities, was approximately 42%.",
      "score": -0.765
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect overall spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans."
  ]
}